Zybiraa 250Mg Tablet belongs to the group of medicines called androgen biosynthesis inhibitors, indicated in combination with prednisone or prednisolone to treat prostate cancer in adult men that have spread to other body parts. Zybiraa 250Mg Tablet contains ‘Abiraterone’ that works by stopping the body from making testosterone, thereby slowing the growth of prostate cancer. It is indicated in patients with metastatic castration-resistant prostate cancer (CRPC) who have received prior chemotherapy containing docetaxel and metastatic high-risk castration-sensitive prostate cancer (CSPC). Zybiraa 250Mg Tablet is prescribed in the early stages of the disease, where it is still responding to hormone therapy. It is used with androgen deprivation therapy (a treatment that lowers testosterone).

FAQs

How does Zybiraa 250Mg Tablet work?

Zybiraa 250Mg Tablet works by stopping the body from making testosterone, thereby slowing the growth of prostate cancer.

Why is prednisolone/prednisone prescribed along with Zybiraa 250Mg Tablet ?

Prednisolone/prednisone is prescribed along with Zybiraa 250Mg Tablet to lower the chances of getting high blood pressure, fluid retention (having too much water in the body), or low blood potassium levels.

Is it safe to take Ra-233 with Zybiraa 250Mg Tablet ?

Zybiraa 250Mg Tablet should not be given along with Ra-233 (a radioactive isotope used to treat prostate cancer) due to the increased risk of bone fracture or death. If you are prescribed to take Ra-233 following treatment with Zybiraa 250Mg Tablet and prednisolone/prednisone, you must wait five days before starting treatment with Ra-233.